Gene expression signatures from microarray experiments promise to provide important prognostic tools for predicting disease outcome or response to treatment. A number of microarray studies in various cancers have reported such gene signatures. However, the overlap of gene signatures in the same disease has been limited so far, and some reported signatures have not been reproduced in other populations. Clearly, the methods used for verifying novel gene signatures need improvement. In this paper, we describe an experiment in which microarrays and sample hybridization are designed according to the statistical principles of randomization, replication, and blocking. Our results show that such designs provide unbiased estimation of differential expression levels as well as powerful tests for them.
THE POTENTIAL OF USING GENE EXPRESSION SIGNATURES AS DIAGNOSTIC TOOLS
The ability to analyze the expression of a large number of genes in a single experiment using microarrays has revolutionized biomedical research, particularly cancer research. Multiple microarray studies in various different cancers have resulted in gene signatures which have been proposed to be directly associated with risk of disease recurrence, treatment or outcome. For example, by examining the expression of 25,000 genes in tumors from young (< 55 years at diagnosis), node-negative, sporadic breast cancer cases, van't Veer et al. identified a 70 gene signature that was strongly predictive of short interval to distant metastasis [1] . Van de Vijver et al. confirmed these findings in a larger group of 295 young patients (< 53 years at diagnosis) with stage I or stage II disease [2] . Also, Ma et al. performed microarray analysis on 22,000 genes in frozen breast tumors and microdissected tumor cells from 60 patients that had received Tamoxifen as only adjuvant therapy [3] . From this analysis two genes emerged, HOXB13 and IL17BR, that showed the strongest correlation with clinical outcome. Many similar studies have been performed in other diseases including renal cancer [4, 5] , non-small cell lung cancer (reviewed in [6] ) and in the various different leukemias (reviewed in [7] ).
However, several problems with microarray analysis have recently emerged. First, microarray analyses performed in different research laboratories have resulted in limited overlap in gene signatures in the same disease.
In a study on gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Wang et al. recently found a 76-gene signature strongly predictive of metastatic disease [8] . However, despite many similarities in study design, only three genes overlapped with the van't Veer et al [1] and van de Vijver et al [2] studies, namely cyclin E2, origin recognition complex and a TNF superfamily protein [8] . Similarly, in diffuse large B-cell lymphoma two groups have identified gene signatures to predict outcome in this heterogenous cancer. Rosenwald et al. reported a 17 gene signature [9] and Shipp et al. reported a 13 gene signature [10] , both predicting survival after conventional chemotherapy.
Interestingly there was no overlap in the two gene and IL17BR for treatment outcome in breast cancer [11] reported originally by Ma et al. [3] .
It is clear that if microarrays are to be used as a diagnostic device, the results need to be reproducible and sensitivity and specificity of the signatures need to be 
RANDOMIZATION
If placement of the biological samples onto microarrays is not randomized, then observed differences in expression levels may be due to batch processing or position effects. To avoid such bias and confounding, we believe the placement of biological samples onto the microarrays should be randomized. If placement of the probes on microarrays is not randomized, a prediction algorithm derived from one type of microarrays may contain bias and the prediction therefore not reproducible when expression levels are measured with another type of microarrays. To avoid such bias, we recommend that the placement of probes on the microarrays be randomized as well.
REPLICATION
Measurements on gene expression levels inherently contain variability. To reliably estimate each patient's gene expression levels, we recommend each gene of a patient be probed with replicated probes or probe sets, if sample quantity and manufacturing technology allows it.
AN EXAMPLE TO DEMONSTRATE SENSITIVITY AND SPECIFICITY
To demonstrate the sensitivity and specificity of statistically designed microarrays, we conducted a proofof-concept study using samples with known differences. 
BACKGROUND CORRECTION AND ARRAY NORMALIZATION
We performed background correction as described in Irizarry et al. [22] . With our design, every combination appears twelve times in the experiment, once in each row of every array, and three times in each column over the four arrays. This balances potential well position effects. Also, with this design, every combination appears exactly three times in each array, so it is reasonable to expect the distribution of the expressions to be the same across the arrays. We therefore applied quantile normalization to the four arrays as described in
Bolstad et al. [23] . Specifically, background-adjusted PM intensities for each gene from each array were combined together as a single vector of measurement.
Quantile normalization was then utilized to equalize the distributions of the four vectors from the four arrays.
SENSITIVITY ANALYSIS
Sensitivity, in the context of gene expression level analysis, means inferring genes that are truly differentially expressed to be differentially expressed. Chang, and Wang [24] and can thus be executed in a step-down fashion. With a bootstrap replication size B of 50,000, the results of our step-down testing are reported in Table 1 under the heading OLS.
We first show that multiple testing based on OLS is competitive with multiple tests based on RMA median polish estimates. We applied the following multiplicity adjustment methods which do not take into account the joint distribution of the test statistics to RMA estimates:
the single-step method based on the Bonferroni inequality, Holm's step-down method based on the Bonferroni inequality, Hochberg step-up method based on Simes' inequality, Sidak's single-step method (Sidak SS) based on the product inequality, and Sidak step-down method (Sidak SD) based on the product inequality, to RMA estimates. We also applied the Westfall and
Young re-sampling method [27] , which does take into account the joint distribution of test statistics, to RMA estimates. P-values were computed by complete enumeration of all permutations. The number of differentially expressed genes inferred by these methods is reported under the headings of Bonferroni, Holm, Hochberg, Sidak SS, Sidak SD, and W&Y maxT in Table   1 . Given the same data and the same familywise error rate (FWER) control, product inequality methods will always do at least as well as Bonferroni inequality methods, but not by much (pp. 13-14 in [28] ).
Step-down and step-up methods will always do at least as well as their corresponding single-step methods. Whether a stepdown method or a step-up method does better depends on data (section 7 in [29] ).
Our OLS analysis is a step-down maxT method which takes the correlations among the test statistics into account. So our probe level analysis result is directly comparable to W&Y maxT RMA analysis result. Our OLS result is better than all RMA results. Clearly, the OLS method is competitive with the RMA methods.
We then show that statistically designing microarray experiments leads to better sensitivity. In order to assess the benefit of the proposed block design over unblocked designs, we generated 100 random designs, each design We found that, generally speaking, the more balanced the allocation of treatments to wells is within each array, the higher the sensitivity. For example, Design III in Table 2 Specificity analysis should not be treated as tests for significant difference, as a lack of statistically significant difference can be due to small sample size or noisy data.
Instead, specificity should be treated as an equivalence problem, in analogy to bioequivalence [30] . In our (Equivalence confidence intervals do not necessarily have to be adjusted for multiplicity [30] ). 
